**Abstract**

Cervical cancer is a worldwide public health problem. The leading cause of cervical cancer is persistent infection with high-risk human papillomavirus (HPV). Vaccines exist that protect against high-risk HPV types, and screening programs can detect signs of disease at an early stage, allowing for effective treatment and management of the condition. While being one of the most preventable and treatable forms of cancer, the mortality rate is high, especially in low- and middle-income countries. Early diagnoses, proper staging, and a multidisciplinary approach is the cornerstone of disease management. Surgical treatment, radiation therapy, chemotherapy, immune therapy, and supportive and palliative care are all essential parts of the complex treatment. A simple hysterectomy or brachytherapy for early-stage cervical cancer results in a 5-year OS of more than 98%. For selected patients, radical trachelectomy represents a fertility-sparing treatment option. Radiotherapy (RT), with or without cisplatin-based concurrent chemotherapy after radical or modified radical hysterectomy, is recommended for patients with intermediate- or high-risk features. RT, including brachytherapy plus concurrent chemotherapy, is the treatment of choice for patients with locally advanced disease. Irradiation often provides excellent short-term relief of pain and bleeding, particularly in patients with no history of prior RT.

**Keywords:** cervical cancer, HPV, staging, FIGO, hysterectomy, radiotherapy, brachytherapy, adjuvant radiotherapy
